Widespread renal polycystosis induced by crizotinib.

Di Girolamo, Marco; Paris, Ida; Carbonetti, Francesco; ONESTI, Concetta Elisa; Socciarelli, Fabio; Marchetti, Paolo

doi:10.5301/tj.5000338

Request a copy

Article (Scientific journals)

Widespread renal polycystosis induced by crizotinib.

Di Girolamo, Marco; Paris, Ida; Carbonetti, Francesco et al.

2015 • In Tumori Journal, 101 (4), p. 128-31

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/217586

DOI
10.5301/tj.5000338

PubMed
25953441

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Case report renal polycystosis.pdf

Publisher postprint (3.19 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Oncology

Author, co-author :

Di Girolamo, Marco; Università degli Studi di Roma "La Sapienza" > Department of Radiology

Paris, Ida; Università degli Studi di Roma "La Sapienza" > Departmento of Medical Oncology

Carbonetti, Francesco; Università degli Studi di Roma "La Sapienza" > Department of Radiology

ONESTI, Concetta Elisa ; Università degli Studi di Roma "La Sapienza" > Department of Medical Oncology

Socciarelli, Fabio; Università degli Studi di Roma "La Sapienza"

Marchetti, Paolo; Università degli Studi di Roma "La Sapienza" > Department o Medical Oncology

Language :

English

Title :

Widespread renal polycystosis induced by crizotinib.

Publication date :

July 2015

Journal title :

Tumori Journal

ISSN :

0300-8916

eISSN :

2038-2529

Publisher :

Casa Editrice Ambrosiana, Milano, Italy

Volume :

101

Issue :

Pages :

e128-31

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 January 2018

Statistics

Number of views

48 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120:664-74.
Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist. 2014;19:1008-10.
Heigener DF, Reck M. Crizotinib: recent results. Cancer Res. 2014;201:197-205.
XALORI US Physician Prescribing Information. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed November 2014. (25-11-2014).
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
Jhaveri K, Gupta P, Elmi A, et al. Cystic renal cell carcinomas: do they grow, metastasize, or recur? AJR Am J Roentgenol. 2013;201:W292-6.
Huber J, Winkler A, Jakobi H, et al. Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential. Urol Oncol. 2014;32:37.
Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189-97.
Heller MT, Haarer KA, Thomas E, Thaete FL. Neoplastic and proliferative disorders of the perinephric space. Clin Radiol. 2012;67:e31-41.
Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol. 2000;175:339-42.
Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441-50.
Bata P, Tarnoki AD, Tarnoki DL, et al. Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology. J Res Med Sci. 2014;19:634-8.